Ariad Pharmaceuticals (ARIA) : Geduld E E reduced its stake in Ariad Pharmaceuticals by 62.45% during the most recent quarter end. The investment management company now holds a total of 45,100 shares of Ariad Pharmaceuticals which is valued at $458,216 after selling 75,000 shares in Ariad Pharmaceuticals , the firm said in a disclosure report filed with the SEC on Aug 8, 2016.Ariad Pharmaceuticals makes up approximately 0.63% of Geduld E E’s portfolio.
Other Hedge Funds, Including , Oxford Asset Management reduced its stake in ARIA by selling 225,922 shares or 22.95% in the most recent quarter. The Hedge Fund company now holds 758,519 shares of ARIA which is valued at $7,706,553. Ariad Pharmaceuticals makes up approx 0.30% of Oxford Asset Management’s portfolio.Quantitative Investment Management reduced its stake in ARIA by selling 14,400 shares or 14.46% in the most recent quarter. The Hedge Fund company now holds 85,200 shares of ARIA which is valued at $846,036. Ariad Pharmaceuticals makes up approx 0.04% of Quantitative Investment Management’s portfolio.Concert Wealth Management reduced its stake in ARIA by selling 673 shares or 1.63% in the most recent quarter. The Hedge Fund company now holds 40,686 shares of ARIA which is valued at $386,924. Ariad Pharmaceuticals makes up approx 0.05% of Concert Wealth Management’s portfolio. Smith Asset Management Group Lp added ARIA to its portfolio by purchasing 36,250 company shares during the most recent quarter which is valued at $305,225. Ariad Pharmaceuticals makes up approx 0.01% of Smith Asset Management Group Lp’s portfolio.Msi Financial Services Inc reduced its stake in ARIA by selling 62 shares or 1.2% in the most recent quarter. The Hedge Fund company now holds 5,103 shares of ARIA which is valued at $42,967.
Ariad Pharmaceuticals opened for trading at $10.63 and hit $10.83 on the upside on Monday, eventually ending the session at $10.66, with a gain of 0.76% or 0.08 points. The heightened volatility saw the trading volume jump to 37,54,295 shares. Company has a market cap of $2,054 M.
On the company’s financial health, Ariad Pharmaceuticals reported $0.59 EPS for the quarter, beating the analyst consensus estimate by $ 0.70 according to the earnings call on Jul 28, 2016. Analyst had a consensus of $-0.11. The company had revenue of $68.13 million for the quarter, compared to analysts expectations of $62.11 million. The company’s revenue was up 133.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.28 EPS.
Many Wall Street Analysts have commented on Ariad Pharmaceuticals. Company shares were Reiterated by Barclays on May 11, 2016 to “Underweight”, Firm has raised the Price Target to $ 8 from a previous price target of $6 .
ARIAD Pharmaceuticals Inc. is a global oncology company. The Company is engaged in the discovery development and commercialization of small molecule drug indicated for the treatment of cancer. The Companys product pipeline includes Iclusig (ponatinib) brigatinib (AP26113) AP32788 and ridaforolimus. Iclusig is a tyrosine kinase inhibitor (TKI) which is approved in the United States Europe and Australia for the treatment of adult patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Brigatinib is an investigational inhibitor of anaplastic lymphoma kinase (ALK). AP32788 is an orally active TKI. Ridaforolimus is an investigational inhibitor of the mammalian target of rapamycin (mTOR).